Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

详细信息    查看全文

• 作者：David Miles^a ; ^{david.miles@doctors.org.uk} ; David Cameron^b ; Igor Bondarenko^c ; Lyudmila Manzyuk^d ; Juan Carlos Alcedo^e ; Roberto Ivan Lopez^f ; Seock-Ah Im^g ; Jean-Luc Canon^h ; Yaroslav Shparykⁱ ; Denise A. Yardley^j ; Norikazu Masuda^k ; Jungsil Ro^l ; Neelima Denduluri^m ; Stanislas Hubeauxⁿ ; Cheng Quah^o ; Carlos Bais^o ; Joyce O'Shaughnessy^p
• 关键词：Bevacizumab ; Metastatic breast cancer ; Predictive ; Biomarker ; Double-blind ; VEGF-A ; Weekly paclitaxel ; Prospective
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：70
• 期：Complete
• 页码：146-155
• 全文大小：767 K
• 卷排序：70

文摘

This is the first prospective evaluation of a candidate biomarker for bevacizumab. Adding bevacizumab to paclitaxel significantly improved progression-free survival (primary end-point). Results do not support plasma vascular endothelial growth factor-A as a predictive biomarker for bevacizumab.